Amgen's Subcutaneous TEPEZZA Hits Phase 3 Success in Thyroid Eye Disease

Event summary

  • Amgen's Phase 3 trial for subcutaneous TEPEZZA in moderate-to-severe Thyroid Eye Disease (TED) met primary and key secondary endpoints.
  • 77% of patients achieved a statistically significant proptosis response rate, with a mean reduction of 3.17 mm at week 24.
  • Safety profile consistent with IV TEPEZZA, with mild-to-moderate injection site reactions observed.
  • TEPEZZA has treated over 25,000 patients worldwide since its 2020 approval.

The big picture

Amgen's success with subcutaneous TEPEZZA extends its leadership in TED treatment, addressing a critical unmet need in a rare disease space. The shift from IV to subcutaneous administration could significantly expand patient access and convenience, reinforcing TEPEZZA's market dominance. This development aligns with broader industry trends toward more patient-friendly drug delivery methods, particularly for chronic and rare conditions.

What we're watching

Regulatory Approval
Whether the FDA will approve the subcutaneous formulation based on the Phase 3 data.
Market Expansion
The pace at which Amgen can transition TED patients from IV to subcutaneous TEPEZZA.
Competitive Dynamics
How this advancement affects Amgen's position against potential competitors in the TED space.